Please login to the form below

Not currently logged in
Email:
Password:

Onyx and Bayer settle claim

Bayer HealthCare has reached a settlement with Onyx Pharmaceuticals relating to Onyx's investigational treatment regorafeniba and revised a contract for the marketing of cancer drug Nexavar

Bayer HealthCare has reached a settlement with Onyx Pharmaceuticals relating to Onyx's investigational treatment regorafeniba and revised a contract for the marketing of cancer drug Nexavar (sorafenib).

The regorafenib deal will see Bayer acquire the rights to the drug for a one-time payment of $160m, with the pharmaceutical company having the final decision-making authority for global development and commercialisation.

Onyx will also receive a royalty on any future global net sales of regorafenib in oncology. Bayer will contract the Onyx sales force to promote regorafenib, along with Bayer sales representatives, in the US.

Bayer had previously said it had full ownership of the drug, while Onyx claimed the compound was related to their joint Nexavar project.

Under the revised Nexavar agreement, both Onyx and Bayer are free to use their respective Nexavar sales forces to promote regorafenib and additional products outside of the collaboration. 

Bayer will purchase Onyx's royalty rights for sales of the product in Japan in exchange for a one-time payment to Onyx. Bayer does not have to pay royalties to Onyx on Japanese sales of Nexavar after December 31, 2011.

The new contract settles and dismisses all claims related to the complaint filed by Onyx against Bayer in the US.

12th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications is a fresh thinking health and medical communications agency. Our team is made up of experienced and...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics